Trial participants
auditory or perceptual disorders, a neuromuscular disease, tumor, Cancer
TUMOR, POSTERIOR FOSSA TUMORS, GENETIC DISORDER, CARDIOMYOPATHY, NEUROMUSCULAR DISEASE, POSTERIOR FOSSA TUMOR, CHRONIC LUNG DISEASE, CANCER
We conducted randomized control clinical trial at Children’s Cancer Hospital Foundation 57,357, Cairo between September 2020 and April, 2021. The inclusion criteria include: 1—Children with posterior fossa tumors during follow up, 2—the age of study participants is between 5 and 12 years, 3—time elapsed since the start of treatment is more than 4 months to be in maintenance phase, 4—they can understand verbal command, 5—children with no visual, auditory or perceptual disorders. The exclusion criteria include patients who had a genetic disorder or can neither follow orders nor instructions, a chronic lung disease, sever cardiomyopathy, or a neuromuscular disease that does not relate to tumor.Ninety-two children with posterior fossa tumor participated in the study, but only sixty children treated for posterior fossa tumor met the eligibility criteria as illustrated in Fig. Flow diagram illustrating participants entered the study